Drug updated on 11/1/2024
| Dosage Form | Injection (subcutaneous; 11.3 mg/2.2 mL [5 mg/mL]) |
| Drug Class | Leptin analogs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Latest News
Summary
- This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
- Metreleptin effectively reduced triglycerides and HbA1c (haemoglobin A1c) levels in patients with lipodystrophy across both partial and generalized types, as well as in specific genetic subgroups, including LMNA, PPARG, AGPAT2, and BSCL2. Body Mass Index (BMI) was also lowered in generalized and partial lipodystrophy and specifically in the LMNA and BSCL2 subgroups, though not in PPARG or AGPAT2 subgroups.
- Compared to metreleptin, thiazolidinediones showed effectiveness in lowering HbA1c and triglycerides across all types of lipodystrophy, with HbA1c improvements particularly noted in the PPARG subgroup and triglyceride reductions in the LMNA subgroup. Additionally, recombinant human IGF-1 (rhIGF-1), alone or combined with IGFBP3, improved HbA1c specifically in cases of INSR-related insulin resistance.
- No safety information is available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Myalept (metreleptin) Prescribing Information. | 2022 | Amryt Pharmaceuticals DAC, Dublin, Ireland |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Classification of Congenital Leptin Deficiency | 2024 | The Journal of Clinical Endocrinology and Metabolism |
| Genotype-stratified treatment for monogenic insulin resistance: a systematic review | 2023 | Communications Medicine |
| Systematic review of genotype-stratified treatment for monogenic insulin resistance | 2023 | The Preprint Server for Health Sciences |